SpectraCure P18 System
Phase 3- Indications
- prostate cancer
Company intelligence / Profile preview
SpectraCure
Lund, Skåne län, Swedenspectracure.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
SpectraCure develops a next-generation focal photodynamic therapy system—Q-PRO®—for minimally invasive treatment of localized prostate cancer. The approach combines the established method of photodynamic therapy using verteporfin with advanced laser/light dose planning and real-time dosimetry via their proprietary IDOSE® software. Clinical trials are ongoing in North America and Europe targeting both recurrent and primary localized prostate cancers. Early results have driven recent stock market interest.
- Therapeutic areas
- Oncology
- Modalities
- DevicePhotodynamic therapy (PDT)Small molecule (verteporfin as photosensitizer)
- Industry
- Therapeutic Medical Devices
02
Drug pipeline
1 asset03
Partnerships
Letter of Intent signed with Cheplapharm to secure global supply of the photosensitizing drug used with Q-PRO system; Cheplapharm will provide API supply.
Beyond the preview
Go deeper on SpectraCure.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SpectraCure.